Opendata, web and dolomites

SmallDrugRheuma SIGNED

Discovery of Immune Therapeutic Targets and Immunomodulators for the Development of Novel Therapies in Rheumatoid Arthritis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SmallDrugRheuma project word cloud

Explore the words cloud of the SmallDrugRheuma project. It provides you a very rough idea of what is the project "SmallDrugRheuma" about.

modulation    vivo    cancer    auto    approved    joints    inflammation    immunotherapy    arthropathies    elucidation    modulate    library    partnership    cardiovascular    expertise    productive    libraries    chronic    disabling    competitiveness    small    rnaseq    arthritis    cas9    environment    striking    pharmaceutical    therapies    disease    treat    ra    prevalence    autoimmune    joint    altered    mechanisms    edge    containing    tested    translated    ex    extensive    patients    mechanism    public    counterbalancing    boosting    molecules    multiple    immune    company    originality    prevent    possibilities    technologies    characterizes    ultimately    crispr    frequent    immunology    umbrella    place       chemoproteomics    utility    compounds    pain    progress    drugs    chemical    of    screening    immunotherapeutics    cells    quality    therapeutic    effort    potentially    percentage    employed    treatment    researcher    rheumatoid    diseases    inflammatory    swelling    exist    proof    action    repurposing    career    integrate    private    adulthood    interdisciplinary    candidates    cell    cutting       deformity   

Project "SmallDrugRheuma" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD DE SANTIAGO DE COMPOSTELA 

Organization address
address: COLEXIO DE SAN XEROME PRAZA DO OBRADOIRO S/N
city: SANTIAGO DE COMPOSTELA
postcode: 15782
website: http://www.usc.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-29   to  2020-06-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE SANTIAGO DE COMPOSTELA ES (SANTIAGO DE COMPOSTELA) coordinator 170˙121.00

Map

 Project objective

Rheumatoid Arthritis (RA) is an autoimmune chronic disease, characterized by inflammation in multiple joints, ultimately leading to joint deformity, pain and swelling. RA is one of the most frequent inflammatory arthropathies, with a prevalence of 0.3%-1%, striking during the most productive years of adulthood, and is a chronic disabling condition. No therapies exist to prevent RA, and a high percentage of patients do not respond to currently available therapies. Our research aims to integrate expertise on immunology and cutting-edge screening technologies to identify novel immunotherapeutics for RA based on immune modulation mechanisms. The project makes use of an extensive screening effort using a chemical library (60,000 compounds) containing repurposing drugs (drugs already approved for their use for the treatment of other diseases), targeted libraries and lead-like compounds. The aim of the project is to identify novel small molecules capable to modulate the immune response, counterbalancing the altered inflammatory environment that characterizes RA. Elucidation of the mechanism of action of the candidates (cell type, pathway and target) will take place through state-of-the art technologies such as chemoproteomics, RNASeq or CRISPR/Cas9. Ultimately, the most promising candidates will be tested ex vivo in cells from RA patients, providing a proof-of-concept of the therapeutic utility of the identified mechanism. The project is interdisciplinary and will make progress beyond the state of the art, as the identified immunotherapeutics could also be employed to treat other (auto)immune diseases, as well as being potentially translated to immunotherapy of cancer and cardiovascular diseases. The high-quality and originality of this proposal will open up the best career possibilities for the experienced researcher, and will be carried out under the umbrella of a public-private partnership with a pharmaceutical company, boosting European competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMALLDRUGRHEUMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMALLDRUGRHEUMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ICARUS (2020)

Information Content of locAlisation: fRom classical to qUantum Systems

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

NarrowbandSSL (2019)

Development of Narrow Band Blue and Red Emitting Macromolecules for Solution-Processed Solid State Lighting Devices

Read More